Trial Profile
Quetiapine XR Monotherapy or Adjunctive Therapy to Antidepressants in the Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2016
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Generalised anxiety disorder; Major depressive disorder
- Focus Registrational; Therapeutic Use
- 28 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 13 Dec 2011 Actual patients number (33) added as reported by ClinicalTrials.gov.
- 13 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.